[HTML][HTML] Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with …
LN Cosenso-Martin, LT Giollo-Júnior… - Diabetology & Metabolic …, 2015 - Springer
Background Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
[PDF][PDF] Twelve‑week randomized study to compare the effect of vildagliptin vs. glibenclamide both added‑on to metformin on endothelium function in patients with type …
LN Cosenso-Martin, LT Giollo-Júnior, DD Martineli… - 2015 - academia.edu
Abstract Background: Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2
diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims …
diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims …
[HTML][HTML] Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with …
LN Cosenso-Martin, LT Giollo-Júnior… - Diabetology & …, 2015 - europepmc.org
Background Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 …
LN Cosenso-Martin, LT Giollo-Júnior… - Diabetology & Metabolic …, 2015 - infona.pl
Background Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
[PDF][PDF] Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type …
LN Cosenso-Martin, LT Giollo-Júnior, DD Martineli… - 2015 - researchgate.net
Abstract Background: Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2
diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims …
diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims …
Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 …
LN Cosenso-Martin, LT Giollo-Junior… - Diabetology & …, 2015 - search.ebscohost.com
Abstract Background: Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2
diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims …
diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims …
[PDF][PDF] Twelve‑week randomized study to compare the effect of vildagliptin vs. glibenclamide both added‑on to metformin on endothelium function in patients with type …
LN Cosenso‑Martin, LT Giollo‑Júnior, DD Martineli… - 2015 - Citeseer
Abstract Background: Vildagliptin, a DPP‑4 inhibitor widely used for the treatment of type 2
diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims …
diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims …
[HTML][HTML] Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with …
LN Cosenso-Martin, LT Giollo-Júnior… - Diabetology & …, 2015 - ncbi.nlm.nih.gov
Background Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …
Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 …
LN Cosenso-Martin, LT Giollo-Junior… - Diabetology & …, 2015 - search.proquest.com
Background Cardiovascular disease (CVD) is the main cause of deaths in developing and
developed countries. In Brazil, CVD accounts for more than 30% of the overall mortality rate …
developed countries. In Brazil, CVD accounts for more than 30% of the overall mortality rate …
[HTML][HTML] Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with …
LN Cosenso-Martin… - Diabetology & …, 2015 - dmsjournal.biomedcentral.com
Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes mellitus
(T2DM), shows beneficial effects on endothelial function. This study aims to evaluate the …
(T2DM), shows beneficial effects on endothelial function. This study aims to evaluate the …